Current challenges in applying gene-driven therapies in clinical lung cancer practice

Figure 1 Process of treatment decision in lung cancer. After referral of patients’ lung function tests, blood samples, computed tomography scans, and star climbing tests are reviewed in multidiscipline team (MDT) and the diagnostic plan formed, after which doctor's visit and defined examinations. Treatment decision including operation, radiotherapy and systemic therapy by MDT planning meeting is based on performance status, stage and histology. PET: Positron emission tomography; CT: Computed tomography; EBUS: Endobronchial ultrasound; MDT: Multidiscipline team.

Figure 2 Presenting the history of the European Medicines Agency approvals and reimbursement situation in Finland (40% reimbursement and 100% reimbursement), concerning gene-driven therapies for lung cancer. NTRK: Neurotrophic receptor tyrosine kinase; PET: Positron emission tomography; CT: Computed tomography; EMA: European Medicines Agency; ALK: Anaplastic lymphoma kinase; EGFR: Epidermal growth factor receptor.